Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS)

C. Farsang, M. Lengyel, Sarolta Borbás, Ágnes Zorándi, Bernadett Szórádi Dienes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: The primary objective was to assess the effects of rilmenidine monotherapy and in combination with perindopril on blood pressure (BP) in patients assessed with grade 1 or 2 essential hypertension. The study also examined the effects of 2-year rilmenidine monotherapy on left ventricular hypertrophy (LVH) and on diastolic function of the left ventricle, along with the effects of rilmenidine on left ventricular mass index in hypertensive patients with no LVH, and the relationship between BP reduction and any change in LVH. Research design and methods: Mild-to-moderate hypertensive patients (n = 500) were enrolled in a multicentre 2-year open study and treated with rilmenidine (1-2 mg per day) monotherapy or rilmenidine plus perindopril (2, 4 or 8 mg per day) if control of hypertension was not achieved with rilmenidine monotherapy within 12 weeks. Blood pressure was recorded at regular intervals by the investigators and LVH measured by centralised single-blind echocardiographic reading. Results: Rilmenidine monotherapy (average dose 1.42 mg) produced a significant decrease in BP from the baseline of 163 ± 10/100 ± 5 mmHg to 134 ± 10/86 ± 7 mmHg at 1 year and to 136 ± 10/84 ± 7 mmHg at 2 years (p <0.001 for both). In 188 patients with LVH, the left ventricular mass index was significantly reduced from 161.4 ± 30.5 to 131.3 ± 26.5 at 1 year and to 134.1 ± 26.0 g/m2 at 2 years (p <0.001 for both). Addition of perindopril to those patients whose BP was not normalised by rilmenidine monotherapy after 12 weeks further decreased BP significantly from 150 ± 13/93 ± 8 mmHg to 142 ± 14/89 ± 7 mmHg at the end of the 2nd year. Conclusions: Long-term rilmenidine monotherapy was shown to be efficient in controlling BP and in reducing LVH. The addition of perindopril to rilmenidine monotherapy proved to be effective and well tolerated in those patients who did not respond to rilmenidine alone.

Original languageEnglish
Pages (from-to)205-217
Number of pages13
JournalCurrent Medical Research and Opinion
Volume19
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

rilmenidine
Perindopril
Left Ventricular Hypertrophy
Blood Pressure
Therapeutics
Essential Hypertension

Keywords

  • ACE inhibitors
  • Echocardiography
  • Essential hypertension
  • Imidazoline receptor agonists
  • Left ventricular hypertrophy
  • Perindopril
  • Rilmenidine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). / Farsang, C.; Lengyel, M.; Borbás, Sarolta; Zorándi, Ágnes; Szórádi Dienes, Bernadett.

In: Current Medical Research and Opinion, Vol. 19, No. 3, 2003, p. 205-217.

Research output: Contribution to journalArticle

@article{2e9b58cc14a84b03b2f8249368773fee,
title = "Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS)",
abstract = "Objectives: The primary objective was to assess the effects of rilmenidine monotherapy and in combination with perindopril on blood pressure (BP) in patients assessed with grade 1 or 2 essential hypertension. The study also examined the effects of 2-year rilmenidine monotherapy on left ventricular hypertrophy (LVH) and on diastolic function of the left ventricle, along with the effects of rilmenidine on left ventricular mass index in hypertensive patients with no LVH, and the relationship between BP reduction and any change in LVH. Research design and methods: Mild-to-moderate hypertensive patients (n = 500) were enrolled in a multicentre 2-year open study and treated with rilmenidine (1-2 mg per day) monotherapy or rilmenidine plus perindopril (2, 4 or 8 mg per day) if control of hypertension was not achieved with rilmenidine monotherapy within 12 weeks. Blood pressure was recorded at regular intervals by the investigators and LVH measured by centralised single-blind echocardiographic reading. Results: Rilmenidine monotherapy (average dose 1.42 mg) produced a significant decrease in BP from the baseline of 163 ± 10/100 ± 5 mmHg to 134 ± 10/86 ± 7 mmHg at 1 year and to 136 ± 10/84 ± 7 mmHg at 2 years (p <0.001 for both). In 188 patients with LVH, the left ventricular mass index was significantly reduced from 161.4 ± 30.5 to 131.3 ± 26.5 at 1 year and to 134.1 ± 26.0 g/m2 at 2 years (p <0.001 for both). Addition of perindopril to those patients whose BP was not normalised by rilmenidine monotherapy after 12 weeks further decreased BP significantly from 150 ± 13/93 ± 8 mmHg to 142 ± 14/89 ± 7 mmHg at the end of the 2nd year. Conclusions: Long-term rilmenidine monotherapy was shown to be efficient in controlling BP and in reducing LVH. The addition of perindopril to rilmenidine monotherapy proved to be effective and well tolerated in those patients who did not respond to rilmenidine alone.",
keywords = "ACE inhibitors, Echocardiography, Essential hypertension, Imidazoline receptor agonists, Left ventricular hypertrophy, Perindopril, Rilmenidine",
author = "C. Farsang and M. Lengyel and Sarolta Borb{\'a}s and {\'A}gnes Zor{\'a}ndi and {Sz{\'o}r{\'a}di Dienes}, Bernadett",
year = "2003",
doi = "10.1185/030079903125001659",
language = "English",
volume = "19",
pages = "205--217",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS)

AU - Farsang, C.

AU - Lengyel, M.

AU - Borbás, Sarolta

AU - Zorándi, Ágnes

AU - Szórádi Dienes, Bernadett

PY - 2003

Y1 - 2003

N2 - Objectives: The primary objective was to assess the effects of rilmenidine monotherapy and in combination with perindopril on blood pressure (BP) in patients assessed with grade 1 or 2 essential hypertension. The study also examined the effects of 2-year rilmenidine monotherapy on left ventricular hypertrophy (LVH) and on diastolic function of the left ventricle, along with the effects of rilmenidine on left ventricular mass index in hypertensive patients with no LVH, and the relationship between BP reduction and any change in LVH. Research design and methods: Mild-to-moderate hypertensive patients (n = 500) were enrolled in a multicentre 2-year open study and treated with rilmenidine (1-2 mg per day) monotherapy or rilmenidine plus perindopril (2, 4 or 8 mg per day) if control of hypertension was not achieved with rilmenidine monotherapy within 12 weeks. Blood pressure was recorded at regular intervals by the investigators and LVH measured by centralised single-blind echocardiographic reading. Results: Rilmenidine monotherapy (average dose 1.42 mg) produced a significant decrease in BP from the baseline of 163 ± 10/100 ± 5 mmHg to 134 ± 10/86 ± 7 mmHg at 1 year and to 136 ± 10/84 ± 7 mmHg at 2 years (p <0.001 for both). In 188 patients with LVH, the left ventricular mass index was significantly reduced from 161.4 ± 30.5 to 131.3 ± 26.5 at 1 year and to 134.1 ± 26.0 g/m2 at 2 years (p <0.001 for both). Addition of perindopril to those patients whose BP was not normalised by rilmenidine monotherapy after 12 weeks further decreased BP significantly from 150 ± 13/93 ± 8 mmHg to 142 ± 14/89 ± 7 mmHg at the end of the 2nd year. Conclusions: Long-term rilmenidine monotherapy was shown to be efficient in controlling BP and in reducing LVH. The addition of perindopril to rilmenidine monotherapy proved to be effective and well tolerated in those patients who did not respond to rilmenidine alone.

AB - Objectives: The primary objective was to assess the effects of rilmenidine monotherapy and in combination with perindopril on blood pressure (BP) in patients assessed with grade 1 or 2 essential hypertension. The study also examined the effects of 2-year rilmenidine monotherapy on left ventricular hypertrophy (LVH) and on diastolic function of the left ventricle, along with the effects of rilmenidine on left ventricular mass index in hypertensive patients with no LVH, and the relationship between BP reduction and any change in LVH. Research design and methods: Mild-to-moderate hypertensive patients (n = 500) were enrolled in a multicentre 2-year open study and treated with rilmenidine (1-2 mg per day) monotherapy or rilmenidine plus perindopril (2, 4 or 8 mg per day) if control of hypertension was not achieved with rilmenidine monotherapy within 12 weeks. Blood pressure was recorded at regular intervals by the investigators and LVH measured by centralised single-blind echocardiographic reading. Results: Rilmenidine monotherapy (average dose 1.42 mg) produced a significant decrease in BP from the baseline of 163 ± 10/100 ± 5 mmHg to 134 ± 10/86 ± 7 mmHg at 1 year and to 136 ± 10/84 ± 7 mmHg at 2 years (p <0.001 for both). In 188 patients with LVH, the left ventricular mass index was significantly reduced from 161.4 ± 30.5 to 131.3 ± 26.5 at 1 year and to 134.1 ± 26.0 g/m2 at 2 years (p <0.001 for both). Addition of perindopril to those patients whose BP was not normalised by rilmenidine monotherapy after 12 weeks further decreased BP significantly from 150 ± 13/93 ± 8 mmHg to 142 ± 14/89 ± 7 mmHg at the end of the 2nd year. Conclusions: Long-term rilmenidine monotherapy was shown to be efficient in controlling BP and in reducing LVH. The addition of perindopril to rilmenidine monotherapy proved to be effective and well tolerated in those patients who did not respond to rilmenidine alone.

KW - ACE inhibitors

KW - Echocardiography

KW - Essential hypertension

KW - Imidazoline receptor agonists

KW - Left ventricular hypertrophy

KW - Perindopril

KW - Rilmenidine

UR - http://www.scopus.com/inward/record.url?scp=0037569206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037569206&partnerID=8YFLogxK

U2 - 10.1185/030079903125001659

DO - 10.1185/030079903125001659

M3 - Article

C2 - 12803735

AN - SCOPUS:0037569206

VL - 19

SP - 205

EP - 217

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 3

ER -